Saturday, June 25, 2016

GeneNews resolves TSX, OSC issues

GeneNews resolves TSX, OSC issues

June 16, 2016 by · Leave a Comment 

Tweet GeneNews (TSX:GEN), by raising additional financings via a series of transactions over the past few weeks, and filing its full year 2015 and 2016 first quarter results, has successfully resolved both the Toronto Stock Exchange continued listing review and the management cease trade order granted by the Ontario Securities Commission in March. “The last […]

GeneNews closes note financing with Alumina

GeneNews closes note financing with Alumina

April 28, 2016 by · Leave a Comment 

Tweet GeneNews (TSX:GEN) has executed a definitive financing agreement with Alumina Partners for a second tranche of a non-brokered private placement. Under the accord, GeneNews will draw down on $10-million in structured, unsecured convertible notes, at the company’s option, in installments of $200,000 over a 24-month period. The initial draw will be limited to $200,000 […]

GeneNews provides financing update

GeneNews provides financing update

April 7, 2016 by · Leave a Comment 

Tweet GeneNews (TSX:GEN) has closed the first tranche of a private placement, consisting of the issuance of approximately 5.6 million common shares at a price of 10 cents each, for gross proceeds of approximately $560,000, to be used for working capital. The company also has executed a term sheet with Alumina Partners for a second […]

GeneNews and JTS Health in business acceleration pact

GeneNews and JTS Health in business acceleration pact

March 31, 2016 by · Leave a Comment 

Tweet GeneNews (TSX:GEN) has entered into a collaboration agreement with JTS Health Partners of Atlanta to accelerate adoption of GeneNews’ menu of proprietary cancer tests, including its lead ColonSentry blood-test for assessing an individual’s current risk for colorectal cancer. JTS, a leading national healthcare management consulting and professional services firm, will also work to maximize […]

GeneNews arranging private placement

GeneNews arranging private placement

March 14, 2016 by · Leave a Comment 

Tweet GeneNews (TSX:GEN) is undertaking a non-brokered private placement of up to 50 million common shares at a price of 10 cents apiece, or $5-million. Any remaining unfunded portion of the offering may be raised with the issuance of a senior secured, collateralized convertible debenture. If needed, this convertible debenture would be issued with a […]

GeneNews acquires full control of IDL

GeneNews acquires full control of IDL

March 4, 2016 by · Leave a Comment 

Tweet A GeneNews (TSX:GEN) U.S. subsidiary has agreed to acquire Cobalt Healthcare Consultants’ 50% interest in the Innovative Diagnostic Laboratory (IDL) joint venture so that GeneNews will have full ownership of IDL. Under the accord, GeneNews will assume Cobalt’s liability relating to its $1-million secured demand promissory note, payable to former IDL partner, HDL USA […]

GeneNews gets promising early results from lung cancer study

GeneNews gets promising early results from lung cancer study

September 8, 2015 by · Leave a Comment 

Tweet GeneNews (TSX:GEN) has received encouraging early results from the largest randomized trial ever conducted for the early detection of lung cancer using EarlyCDT-Lung, an autoantibody biomarker blood test. The findings were announced at the International Association for the Study of Lung Cancer’s World Conference on Lung Cancer. The National Health Service (NHS) Scotland-sponsored Early […]

GeneNews’ IDL to provide prostate testing to MD Anderson

GeneNews’ IDL to provide prostate testing to MD Anderson

September 4, 2015 by · Leave a Comment 

Tweet GeneNews’ (TSX:GEN) Innovative Diagnostic Laboratory (IDL) joint venture has agreed to provide its prostate health index (PHI) testing services to MD Anderson Cancer Center. “There is significant interest in IDL’s early cancer diagnostic tests from hospital groups and large physician practice groups,” said James Howard-Tripp, executive chairman of GeneNews, said in a statement. “IDL […]

GeneNews names Dr. Joel Brill as CMO

GeneNews names Dr. Joel Brill as CMO

August 5, 2015 by · Leave a Comment 

Tweet GeneNews (TSX:GEN) has appointed Dr. Joel Brill as CMO of its Innovative Diagnostic Laboratory joint-venture. In his new role, Dr. Brill will assume leadership responsibility for the medical aspects of IDL’s laboratory, and act as the company’s medical lead with physicians, patients and insurance providers. Dr. Brill will serve on IDL’s executive committee as […]

GeneNews arranging private placement

GeneNews arranging private placement

July 15, 2015 by · Leave a Comment 

Tweet GeneNews (TSX:GEN) is proposing to complete a private placement of up to 8,668,240 units at a price of 35 cents each for gross proceeds of slightly more than $3-million. Each unit consists of one common share and one-half of a warrant, with each whole warrant entitling the holder to purchase an additional common share […]

Next Page »

Email Newsletters with Constant Contact
Google+